Form 4: Annovis Bio CEO Maria-Luisa Maccecchini Reports Stock Transactions and Option Grants

Maria-Luisa Maccecchini, President and CEO of Annovis Bio, Inc., reports charitable donations of common stock and the grant of stock options contingent upon shareholder approval of an equity incentive plan amendment.

Summary

• Maria-Luisa Maccecchini, the President and CEO of Annovis Bio, Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• She made charitable gifts of 10,000 shares of common stock on each of March 28, 2024, March 30, 2024 and March 31, 2024.
• These gifts resulted in a decrease in her directly held shares from 1,088,459 to 1,068,459.
• Maccecchini was also granted stock options on November 17, 2023, to purchase 252,000 shares at an exercise price of $6.07, vesting in quarterly installments through November 17, 2025.
• Additionally, she received a stock option for 108,800 shares at $6.07, vesting immediately, in lieu of a cash bonus for the 2023 fiscal year.
• Both option grants were contingent upon shareholder approval of an amendment to the 2019 Equity Incentive Plan, which increased the number of issuable shares from 2,000,000 to 3,000,000; this amendment was approved on June 12, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports transactions and grants, with no explicit positive or negative implications for the company's performance. The stock options are a positive incentive for the CEO, but the charitable donations are a personal matter.

Positives

• The granting of stock options to the CEO can align her interests with those of the shareholders, incentivizing her to increase the company's value.
• The immediate vesting of 108,800 shares suggests a strong incentive for immediate performance.
• Shareholder approval of the equity incentive plan amendment indicates support for the company's compensation strategy.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders.
• The vesting schedule of the options is fairly standard, with quarterly installments over a two-year period for one grant and immediate vesting for the other.
• The exercise price of $6.07 would need to be compared to the current market price of ANVS to determine the potential value to the executive.

Stakeholder Impact

• Shareholders may view the stock option grants as a positive incentive for the CEO.
• The charitable donations have no direct impact on stakeholders.

Key Dates